[Clinical and microbiological effectiveness of Helicobacter pylori eradication treatment with triple therapy]

To estimate the eradication rate of Helicobacter pylori (HP) with triple therapy (amoxicillin 1g/12h, clarithromycin 500mg/12h, and omeprazole 20mg/12h/for 14 days) and to evaluate its clinical effectiveness in improving symptoms associated with HP infection. This is an observational, prospective, exposed cohort study.

Prospective observational cohort study of exposed groups.

Urban health area with follow-up in primary care.

A total of 125 patients (68% women, 32% men) with untreated HP infection or who had not received eradication treatment in the last year were included, with a mean age of 52.2 years (SD ±17.5).

Three visits were conducted. During visit 1, informed consent was obtained, the main and secondary symptoms were recorded, and treatment was prescribed. In visit 2, after completing the treatment, adverse effects, adherence (Morisky-Green test), and clinical evolution were recorded. In visit 3, the eradication test result was verified.

Demographic, symptomatology, eradication, adherence, and adverse effects variables were collected.

The eradication rate was 92% (95% CI: 85.90-95.60%). Of these, 93.90% (95% CI: 88-97%) showed improvement or resolution of their symptoms. Therapeutic adherence was 80.80% (95% CI: 73.02-86.74%). Adverse effects appeared in 41.60% of patients, of which 35.20% were digestive-related.

The study supports triple therapy as a first-line option for HP infection in primary care in our setting. The majority of patients experienced a progressive improvement in their symptoms.